Identification

Name
Simvastatin
Accession Number
DB00641  (APRD00104)
Type
Small Molecule
Groups
Approved
Description

Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL receptors, it increases breakdown of LDL cholesterol. [PubChem]

Structure
Thumb
Synonyms
  • 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
  • Simvastatin
  • Simvastatina
  • Simvastatine
  • Simvastatinum
  • Synvinolin
External IDs
C10AA01 / MK 733 / MK-0733 / MK-733
Product Ingredients
IngredientUNIICASInChI Key
Acetyl simvastatin171OXS3HEK145576-25-6OHVWRJDVJRNCPE-BIKFJBPRSA-N
Tenivastatin sodium2L6JSY5YGL101314-97-0RLWRROYWKHUVKF-OKDJMAGBSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act SimvastatinTablet10 mgOralActavis Pharma Company2003-09-26Not applicableCanada
Act SimvastatinTablet80 mgOralActavis Pharma Company2003-09-26Not applicableCanada
Act SimvastatinTablet5 mgOralActavis Pharma Company2003-09-26Not applicableCanada
Act SimvastatinTablet20 mgOralActavis Pharma Company2003-09-26Not applicableCanada
Act SimvastatinTablet40 mgOralActavis Pharma Company2003-09-26Not applicableCanada
Auro-simvastatinTablet20 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-simvastatinTablet40 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-simvastatinTablet80 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-simvastatinTablet10 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-simvastatinTablet5 mgOralAuro Pharma Inc2013-07-08Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-simvastatinTablet80 mgOralApotex Corporation2002-12-20Not applicableCanada
Apo-simvastatinTablet20 mgOralApotex Corporation2002-12-20Not applicableCanada
Apo-simvastatinTablet5 mgOralApotex Corporation2002-12-20Not applicableCanada
Apo-simvastatinTablet40 mgOralApotex Corporation2002-12-20Not applicableCanada
Apo-simvastatinTablet10 mgOralApotex Corporation2002-12-20Not applicableCanada
SimvastatinTablet20 mg/1OralPhysicians Total Care, Inc.2008-07-21Not applicableUs
SimvastatinTablet, film coated5 mg/1OralRanbaxy Inc.2006-12-20Not applicableUs
SimvastatinTablet, film coated40 mg/1OralPreferreed Pharmaceuticals Inc.2012-02-28Not applicableUs
SimvastatinTablet, film coated20 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
SimvastatinTablet, film coated20 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2012-11-22Not applicableUs
International/Other Brands
Cholestat (Kalbe) / Colemin (Biohorm) / Labistatin (Sandoz) / Lipex (Merck Sharp & Dohme) / Lodales (Sanofi-Aventis) / Medipo (Mediolanum Farmaceutici) / Nivelipol (Temis-Lostalo) / Simovil (Merck Sharp & Dohme) / Sinvacor (Merck Sharp & Dohme) / Sivastin (Sigma-Tau) / Sivatin (Rowex) / Sivinar (Anfarm) / Sorfox (Galex) / Sotovastin (Bros) / Starezin (Leovan Pharmaceuticals) / Starstat (Lupin) / Starzoko (Daewoong) / Stasiva (Pharmanel) / Statex (Pliva) / Staticor (Darnitsa) / Statinal (Alet Pharmaceuticals) / Stativer (Iapharm) / Zocor
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CholibSimvastatin (20 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
CholibSimvastatin (40 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
CholibSimvastatin (40 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
CholibSimvastatin (20 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
CholibSimvastatin (40 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
CholibSimvastatin (20 mg) + Fenofibrate (145 mg)Tablet, film coatedOralAbbott2013-08-26Not applicableEu
Ezetimibe and SimvastatinSimvastatin (10 mg/1) + Ezetimibe (10 mg/1)TabletOralGolden State Medical Supply2017-04-26Not applicableUs
Ezetimibe and SimvastatinSimvastatin (10 mg/1) + Ezetimibe (10 mg/1)TabletOralDr. Reddy’s Laboratories Inc.2017-04-26Not applicableUs
Ezetimibe and SimvastatinSimvastatin (10 mg/1) + Ezetimibe (10 mg/1)Tablet, film coatedOralImpax Generics2017-04-26Not applicableUs
Ezetimibe and SimvastatinSimvastatin (80 mg/1) + Ezetimibe (10 mg/1)Tablet, film coatedOralImpax Generics2017-04-26Not applicableUs
Categories
UNII
AGG2FN16EV
CAS number
79902-63-9
Weight
Average: 418.5662
Monoisotopic: 418.271924326
Chemical Formula
C25H38O5
InChI Key
RYMZZMVNJRMUDD-HGQWONQESA-N
InChI
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
IUPAC Name
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
SMILES

Pharmacology

Indication

For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia.

Structured Indications
Pharmacodynamics

Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. Simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B.

Mechanism of action

Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed in vivo to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
NIntegrin beta-2
other
Human
UIntegrin alpha-L
inhibitor
Human
Absorption

Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the availability of the drug in the systemic is low. Peak plasma concentration occurs 1.3 - 2.4 hours after administration.

Volume of distribution

Simvastatin can cross the blood-brain-barrier.

Protein binding

Both simvastatin and its β-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins.

Metabolism

Hepatic, simvastatin is a substrate for CYP3A4. The major active metabolites of simvastatin are β-hydroxyacid metabolite and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives

Route of elimination

Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.

Half life

3 hours

Clearance
Not Available
Toxicity

The most common adverse reactions that lead to discontinuation of therapy include gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Simvastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose simvastatin.Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T AlleleEffect Directly StudiedPatients with this genotype have a lesser reduction in LDL cholesterol with simvastatin.Details
Solute carrier organic anion transporter family member 1B1SLCO1B1*5(C;C) / (C;T)T > CADR Directly StudiedThe presence of this genotype in SLCO1B1 is associated with an increased risk of myopathy when treated with simvastatin.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Simvastatin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Simvastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Simvastatin can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbafunginThe risk or severity of adverse effects can be increased when Abafungin is combined with Simvastatin.Investigational
AbirateroneThe serum concentration of Simvastatin can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Simvastatin.Approved
AcenocoumarolSimvastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Simvastatin.Approved
AcetazolamideThe serum concentration of Simvastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Simvastatin.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Simvastatin.Approved
AlbaconazoleThe risk or severity of adverse effects can be increased when Albaconazole is combined with Simvastatin.Investigational
AldesleukinThe serum concentration of Simvastatin can be increased when it is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Simvastatin.Experimental
AlgeldrateThe serum concentration of Simvastatin can be decreased when it is combined with Algeldrate.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Simvastatin.Approved, Investigational
AlmagateThe serum concentration of Simvastatin can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Simvastatin can be decreased when it is combined with Almasilate.Experimental
AlogliptinThe serum concentration of Simvastatin can be increased when it is combined with Alogliptin.Approved
AloglutamolThe serum concentration of Simvastatin can be decreased when it is combined with Aloglutamol.Experimental
Alpha-1-proteinase inhibitorThe serum concentration of Simvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe serum concentration of Simvastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Simvastatin can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Simvastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Simvastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Simvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Simvastatin.Approved, Investigational
AmbroxolThe serum concentration of Simvastatin can be increased when it is combined with Ambroxol.Approved
AmiodaroneThe metabolism of Simvastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Simvastatin.Approved
AmlodipineThe serum concentration of Simvastatin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Simvastatin.Approved
AmprenavirThe serum concentration of Simvastatin can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Simvastatin.Approved
AnastrozoleThe serum concentration of Simvastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Simvastatin can be increased when it is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Simvastatin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Simvastatin can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Simvastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Simvastatin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Simvastatin can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Simvastatin.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Simvastatin.Approved, Investigational
ArtemetherThe metabolism of Simvastatin can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Simvastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Simvastatin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Simvastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Simvastatin.Approved
AtomoxetineThe metabolism of Simvastatin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Simvastatin is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Simvastatin.Approved, Investigational
AzelastineThe serum concentration of Simvastatin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Simvastatin.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Simvastatin.Investigational
AzithromycinAzithromycin may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Simvastatin.Approved
BatimastatThe serum concentration of Simvastatin can be increased when it is combined with Batimastat.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Simvastatin.Approved, Investigational
BenazeprilThe serum concentration of Simvastatin can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Simvastatin.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Simvastatin.Approved
BenzamidineThe serum concentration of Simvastatin can be increased when it is combined with Benzamidine.Experimental
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Simvastatin.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Simvastatin.Approved, Vet Approved
BetaxololThe metabolism of Simvastatin can be decreased when combined with Betaxolol.Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
BicalutamideThe serum concentration of Simvastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Simvastatin can be increased when it is combined with Bifonazole.Approved
Bismuth SubcitrateThe serum concentration of Simvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Simvastatin can be decreased when it is combined with Bismuth subnitrate.Experimental
BivalirudinThe serum concentration of Simvastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Simvastatin can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Simvastatin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Simvastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Simvastatin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Simvastatin.Approved, Investigational
BuprenorphineThe serum concentration of Simvastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Simvastatin can be decreased when combined with Bupropion.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Simvastatin.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Simvastatin.Approved
CabergolineThe serum concentration of Simvastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Simvastatin.Approved
Calcium CarbonateThe serum concentration of Simvastatin can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Simvastatin can be decreased when it is combined with Calcium silicate.Experimental
CamostatThe serum concentration of Simvastatin can be increased when it is combined with Camostat.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Simvastatin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.Approved
CandoxatrilThe serum concentration of Simvastatin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Simvastatin can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe serum concentration of Simvastatin can be increased when it is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Simvastatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Simvastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of adverse effects can be increased when Carbomycin is combined with Simvastatin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Simvastatin.Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Simvastatin.Approved
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Simvastatin.Experimental
CaspofunginThe serum concentration of Simvastatin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Simvastatin can be decreased when combined with Celecoxib.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Simvastatin.Withdrawn
ChloramphenicolThe serum concentration of Simvastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Simvastatin can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Simvastatin.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Simvastatin can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Simvastatin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Simvastatin can be increased when it is combined with Cholesterol.Experimental
ChymostatinThe serum concentration of Simvastatin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Simvastatin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Simvastatin can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Simvastatin.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Simvastatin.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Simvastatin.Approved
CinacalcetThe metabolism of Simvastatin can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Simvastatin.Approved
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Simvastatin.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Simvastatin.Approved, Investigational
CisaprideThe serum concentration of Simvastatin can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Simvastatin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Simvastatin.Approved
ClarithromycinThe serum concentration of Simvastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Simvastatin can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Simvastatin.Approved
ClindamycinThe serum concentration of Simvastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Simvastatin.Approved, Illicit
ClofazimineThe serum concentration of Simvastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Simvastatin.Approved, Investigational
ClomipramineThe metabolism of Simvastatin can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Simvastatin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Simvastatin.Approved, Nutraceutical
ClorindioneSimvastatin may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe serum concentration of Simvastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Simvastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Simvastatin.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Simvastatin.Approved
CocaineThe metabolism of Simvastatin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
ConivaptanThe serum concentration of Simvastatin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Simvastatin.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Simvastatin.Approved
Cortisone acetateThe serum concentration of Simvastatin can be increased when it is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Simvastatin can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Simvastatin can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Simvastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Simvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Simvastatin.Approved
DabrafenibThe serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Simvastatin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Simvastatin.Approved
DalfopristinThe serum concentration of Simvastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Simvastatin can be increased when it is combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Simvastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Simvastatin is combined with Daptomycin.Approved, Investigational
DarexabanThe serum concentration of Simvastatin can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Simvastatin can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Simvastatin.Experimental
DasatinibThe serum concentration of Simvastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Simvastatin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Simvastatin.Approved
DeferasiroxThe serum concentration of Simvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Simvastatin can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Simvastatin can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Simvastatin can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Simvastatin can be decreased when combined with Desipramine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Simvastatin.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Simvastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Simvastatin.Approved, Illicit, Vet Approved
DicoumarolSimvastatin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Simvastatin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Simvastatin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Simvastatin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Simvastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Simvastatin.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Simvastatin.Experimental
DihydroergotamineThe metabolism of Simvastatin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Simvastatin.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Simvastatin.Approved
Dimethyl sulfoxideThe serum concentration of Simvastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenadioneSimvastatin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Simvastatin can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Simvastatin.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Simvastatin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Simvastatin.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Simvastatin can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Simvastatin.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Simvastatin.Approved, Investigational
DoxycyclineThe metabolism of Simvastatin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Simvastatin can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Simvastatin can be decreased when combined with Duloxetine.Approved
EcabetThe serum concentration of Simvastatin can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe serum concentration of Simvastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Simvastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Simvastatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Simvastatin.Approved
ElafinThe serum concentration of Simvastatin can be increased when it is combined with Elafin.Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Simvastatin.Approved, Investigational
EliglustatThe metabolism of Simvastatin can be decreased when combined with Eliglustat.Approved
EltrombopagThe serum concentration of Simvastatin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Simvastatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Simvastatin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Simvastatin can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Simvastatin can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Simvastatin.Approved, Investigational
Epigallocatechin GallateThe serum concentration of Simvastatin can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Simvastatin.Approved, Investigational
EpinephrineThe serum concentration of Simvastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe serum concentration of Simvastatin can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Simvastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Simvastatin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Simvastatin.Approved, Investigational
ErythromycinThe serum concentration of Simvastatin can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Simvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Simvastatin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Simvastatin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Simvastatin.Approved
EthanolThe serum concentration of Simvastatin can be increased when it is combined with Ethanol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Simvastatin.Approved
Ethyl biscoumacetateSimvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Simvastatin.Approved
EtoricoxibThe serum concentration of Simvastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Simvastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Simvastatin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Simvastatin.Approved
FaldaprevirThe serum concentration of Simvastatin can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe metabolism of Simvastatin can be decreased when combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Simvastatin.Withdrawn
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Simvastatin.Approved
FentanylThe serum concentration of Simvastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Simvastatin.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Simvastatin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Simvastatin.Approved
FluconazoleThe serum concentration of Simvastatin can be increased when it is combined with Fluconazole.Approved
FluindioneSimvastatin may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Simvastatin.Approved
FluoxetineThe metabolism of Simvastatin can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Simvastatin.Approved
Fluticasone propionateThe serum concentration of Simvastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Simvastatin.Approved
FluvoxamineThe metabolism of Simvastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Simvastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Simvastatin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Simvastatin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Simvastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Simvastatin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Simvastatin.Approved, Investigational
GabexateThe serum concentration of Simvastatin can be increased when it is combined with Gabexate.Investigational
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Simvastatin.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Simvastatin.Approved, Investigational
GeldanamycinThe serum concentration of Simvastatin can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Simvastatin.Approved
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Simvastatin.Approved
GlyburideThe serum concentration of Simvastatin can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Simvastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Simvastatin can be increased when it is combined with GM6001.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Simvastatin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Simvastatin.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Simvastatin.Approved
HistamineThe serum concentration of Simvastatin can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Simvastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Simvastatin.Approved, Vet Approved
HydrotalciteThe serum concentration of Simvastatin can be decreased when it is combined with Hydrotalcite.Experimental
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Simvastatin.Approved
IdelalisibThe serum concentration of Simvastatin can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Simvastatin can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe serum concentration of Simvastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Simvastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe metabolism of Simvastatin can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Simvastatin can be increased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Simvastatin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Simvastatin.Approved
IndinavirThe serum concentration of Simvastatin can be increased when it is combined with Indinavir.Approved
indisulamThe serum concentration of Simvastatin can be increased when it is combined with indisulam.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Simvastatin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Simvastatin.Approved
IrbesartanThe metabolism of Simvastatin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Simvastatin.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Simvastatin.Approved
IsavuconazoniumThe metabolism of Simvastatin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Simvastatin.Approved
IsoflurophateThe serum concentration of Simvastatin can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Simvastatin can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Simvastatin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Simvastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Simvastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Simvastatin.Approved, Vet Approved
IxazomibThe serum concentration of Simvastatin can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Simvastatin can be increased when it is combined with Josamycin.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Simvastatin.Approved
KetoconazoleThe serum concentration of Simvastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Simvastatin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Simvastatin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Simvastatin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Simvastatin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Simvastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Simvastatin.Approved
LapatinibThe metabolism of Simvastatin can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Simvastatin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Simvastatin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Simvastatin.Approved
LepirudinThe serum concentration of Simvastatin can be increased when it is combined with Lepirudin.Approved
LercanidipineThe serum concentration of Simvastatin can be increased when it is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Simvastatin can be increased when it is combined with Letaxaban.Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Simvastatin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Simvastatin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Simvastatin.Approved
LevosalbutamolThe serum concentration of Simvastatin can be increased when it is combined with Levosalbutamol.Approved
LidocaineThe serum concentration of Simvastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Simvastatin.Experimental
LinagliptinThe serum concentration of Simvastatin can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Simvastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Simvastatin.Approved
LomitapideThe serum concentration of Simvastatin can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Simvastatin can be increased when it is combined with Lomustine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Simvastatin.Approved
LopinavirThe serum concentration of Simvastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Simvastatin can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Simvastatin can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Simvastatin.Approved
LovastatinThe metabolism of Simvastatin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Simvastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Simvastatin can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Simvastatin can be decreased when combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Simvastatin can be increased when it is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Simvastatin.Illicit, Withdrawn
MagaldrateThe serum concentration of Simvastatin can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium HydroxideThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium silicate.Experimental
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Simvastatin.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Simvastatin can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Simvastatin.Approved, Investigational
MefloquineThe serum concentration of Simvastatin can be increased when it is combined with Mefloquine.Approved
MelagatranThe serum concentration of Simvastatin can be increased when it is combined with Melagatran.Experimental
MequitazineThe serum concentration of Simvastatin can be increased when it is combined with Mequitazine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Simvastatin.Experimental
MethadoneThe metabolism of Simvastatin can be decreased when combined with Methadone.Approved
MethazolamideThe serum concentration of Simvastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Simvastatin can be increased when it is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Simvastatin.Approved
MethotrimeprazineThe metabolism of Simvastatin can be decreased when combined with Methotrimeprazine.Approved
MethylergometrineThe serum concentration of Simvastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Simvastatin.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Simvastatin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Simvastatin.Approved, Investigational
MetronidazoleThe serum concentration of Simvastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Simvastatin can be increased when it is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Simvastatin.Experimental
MibefradilThe serum concentration of Simvastatin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Simvastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Simvastatin.Approved, Illicit
MidostaurinThe metabolism of Simvastatin can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Simvastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Simvastatin.Approved
MirtazapineThe serum concentration of Simvastatin can be increased when it is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Simvastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Simvastatin.Approved, Investigational
MoexiprilThe serum concentration of Simvastatin can be increased when it is combined with Moexipril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Simvastatin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simvastatin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Simvastatin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololThe serum concentration of Nadolol can be increased when it is combined with Simvastatin.Approved
NafamostatThe serum concentration of Simvastatin can be increased when it is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Simvastatin.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Simvastatin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Simvastatin.Approved, Vet Approved
NefazodoneThe serum concentration of Simvastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Simvastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Simvastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Simvastatin can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Simvastatin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Simvastatin.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Simvastatin.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Simvastatin.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Simvastatin.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Simvastatin.Experimental
NilotinibThe metabolism of Simvastatin can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Simvastatin.Experimental
NilvadipineThe serum concentration of Simvastatin can be increased when it is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Simvastatin.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Simvastatin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Simvastatin.Approved
NisoldipineThe serum concentration of Simvastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Simvastatin can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe serum concentration of Simvastatin can be increased when it is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Simvastatin can be increased when it is combined with Nitroaspirin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Simvastatin.Approved
NorfloxacinThe serum concentration of Simvastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Simvastatin can be increased when it is combined with Noscapine.Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Simvastatin.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Simvastatin.Approved, Investigational
OlaparibThe metabolism of Simvastatin can be decreased when combined with Olaparib.Approved
OleandomycinThe risk or severity of adverse effects can be increased when Oleandomycin is combined with Simvastatin.Vet Approved
OmapatrilatThe serum concentration of Simvastatin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Simvastatin.Approved
OmeprazoleThe serum concentration of Simvastatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Simvastatin.Experimental
OsimertinibThe serum concentration of Simvastatin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Simvastatin can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Simvastatin.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Simvastatin.Approved
OxybutyninThe serum concentration of Simvastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Simvastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Simvastatin.Approved, Vet Approved
PalbociclibThe serum concentration of Simvastatin can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Simvastatin can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe serum concentration of Simvastatin can be increased when it is combined with Paramethasone.Approved
ParoxetineThe metabolism of Simvastatin can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibSimvastatin may increase the hepatotoxic activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Simvastatin can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe serum concentration of Simvastatin can be increased when it is combined with Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Simvastatin.Approved
PerindoprilThe serum concentration of Simvastatin can be increased when it is combined with Perindopril.Approved
PhenelzineThe serum concentration of Simvastatin can be increased when it is combined with Phenelzine.Approved
PhenindioneSimvastatin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Simvastatin can be increased when combined with Phenobarbital.Approved
PhenprocoumonSimvastatin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Simvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Simvastatin can be increased when it is combined with Phosphoramidon.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Simvastatin.Approved
PilocarpineThe serum concentration of Simvastatin can be increased when it is combined with Pilocarpine.Approved
PimozideThe serum concentration of Simvastatin can be increased when it is combined with Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Simvastatin.Approved
PioglitazoneThe metabolism of Simvastatin can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Simvastatin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Simvastatin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Simvastatin.Approved
PosaconazoleThe serum concentration of Simvastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Simvastatin.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Simvastatin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Simvastatin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Simvastatin.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Simvastatin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Simvastatin.Withdrawn
PrimaquineThe serum concentration of Simvastatin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Simvastatin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Simvastatin can be increased when it is combined with Prinomastat.Investigational
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Simvastatin.Approved, Vet Approved
PromazineThe metabolism of Simvastatin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe serum concentration of Simvastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Simvastatin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Simvastatin.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Simvastatin.Approved
QuinaprilThe serum concentration of Simvastatin can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Simvastatin can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Simvastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Simvastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Simvastatin can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Simvastatin can be increased when it is combined with Racecadotril.Investigational
RaloxifeneThe serum concentration of Simvastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
RamiprilThe serum concentration of Simvastatin can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Simvastatin.Approved
RanolazineThe serum concentration of Simvastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RavuconazoleThe risk or severity of adverse effects can be increased when Ravuconazole is combined with Simvastatin.Investigational
RegorafenibThe serum concentration of Simvastatin can be increased when it is combined with Regorafenib.Approved
RemikirenThe serum concentration of Simvastatin can be increased when it is combined with Remikiren.Approved
RepaglinideThe serum concentration of Simvastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Simvastatin.Approved
ResveratrolThe serum concentration of Simvastatin can be increased when it is combined with Resveratrol.Experimental, Investigational
RifabutinThe metabolism of Simvastatin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Simvastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Simvastatin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Simvastatin.Approved, Investigational
RilpivirineThe serum concentration of Simvastatin can be increased when it is combined with Rilpivirine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Simvastatin.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Simvastatin.Approved, Investigational
RitonavirThe serum concentration of Simvastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Simvastatin can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe serum concentration of Simvastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Simvastatin can be decreased when combined with Rolapitant.Approved
RolitetracyclineThe serum concentration of Simvastatin can be increased when it is combined with Rolitetracycline.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Simvastatin.Approved, Investigational
RopiniroleThe metabolism of Simvastatin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Simvastatin can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Simvastatin.Approved
RoxithromycinThe serum concentration of Simvastatin can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RutinThe serum concentration of Simvastatin can be increased when it is combined with Rutin.Experimental
S-3304The serum concentration of Simvastatin can be increased when it is combined with S-3304.Investigational
SalbutamolThe serum concentration of Simvastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Simvastatin.Approved, Vet Approved
SaquinavirThe serum concentration of Simvastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Simvastatin can be increased when it is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Simvastatin.Approved
SecobarbitalThe metabolism of Simvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Simvastatin.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Simvastatin.Approved
SertralineThe metabolism of Simvastatin can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Simvastatin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Simvastatin.Approved
SiltuximabThe serum concentration of Simvastatin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simvastatin can be increased when it is combined with Simeprevir.Approved
SirolimusThe serum concentration of Simvastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Simvastatin can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe serum concentration of Simvastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Simvastatin can be increased when it is combined with Sivelestat.Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Simvastatin.Approved
SolithromycinThe risk or severity of adverse effects can be increased when Solithromycin is combined with Simvastatin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Simvastatin.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Simvastatin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Simvastatin.Experimental
SpiramycinThe risk or severity of adverse effects can be increased when Spiramycin is combined with Simvastatin.Approved
SpiraprilThe serum concentration of Simvastatin can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Simvastatin can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Simvastatin can be increased when it is combined with Stiripentol.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Simvastatin.Approved
SulfamethoxazoleThe metabolism of Simvastatin can be decreased when combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Simvastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Simvastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Simvastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Simvastatin.Approved, Investigational
TadalafilThe serum concentration of Simvastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Simvastatin.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Simvastatin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Simvastatin.Approved
TelaprevirThe serum concentration of Simvastatin can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Simvastatin can be increased when it is combined with Telithromycin.Approved
TemocaprilThe serum concentration of Simvastatin can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Simvastatin.Approved
TeniposideThe serum concentration of Simvastatin can be increased when it is combined with Teniposide.Approved
TerbinafineThe metabolism of Simvastatin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Simvastatin.Approved
TerfenadineThe serum concentration of Simvastatin can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Simvastatin.Experimental
TeriflunomideThe serum concentration of Simvastatin can be increased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Simvastatin.Experimental
TesmilifeneThe serum concentration of Simvastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Simvastatin can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineThe serum concentration of Simvastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Simvastatin.Investigational
ThiopentalThe serum concentration of Simvastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Simvastatin.Withdrawn
ThiorphanThe serum concentration of Simvastatin can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe serum concentration of Simvastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Simvastatin can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Simvastatin.Approved
TioclomarolSimvastatin may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe serum concentration of Simvastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Simvastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Simvastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe serum concentration of Simvastatin can be increased when it is combined with Tofisopam.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Simvastatin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Simvastatin.Approved
TopiroxostatThe metabolism of Simvastatin can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Simvastatin.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Simvastatin.Approved, Investigational
TrabectedinSimvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Simvastatin can be increased when it is combined with Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Simvastatin can be increased when it is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Simvastatin.Approved, Investigational
TranylcypromineThe metabolism of Simvastatin can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Simvastatin.Approved
TrimethoprimThe metabolism of Simvastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe serum concentration of Simvastatin can be increased when it is combined with Troglitazone.Withdrawn
TroleandomycinThe serum concentration of Simvastatin can be increased when it is combined with Troleandomycin.Approved
TylosinThe risk or severity of adverse effects can be increased when Tylosin is combined with Simvastatin.Vet Approved
UbenimexThe serum concentration of Simvastatin can be increased when it is combined with Ubenimex.Experimental
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Simvastatin.Experimental
UlinastatinThe serum concentration of Simvastatin can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Simvastatin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Simvastatin.Approved
Valproic AcidThe serum concentration of Simvastatin can be increased when it is combined with Valproic Acid.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Simvastatin.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Simvastatin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Simvastatin.Approved
VenlafaxineThe metabolism of Simvastatin can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Simvastatin can be increased when it is combined with Verapamil.Approved
VildagliptinThe serum concentration of Simvastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Simvastatin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Simvastatin.Approved, Investigational
VinorelbineThe serum concentration of Simvastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Simvastatin.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Simvastatin.Approved
VoriconazoleThe serum concentration of Simvastatin can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Simvastatin.Approved
WarfarinSimvastatin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Simvastatin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Simvastatin.Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Simvastatin can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe serum concentration of Simvastatin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Simvastatin.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Simvastatin.Approved
ZiprasidoneThe metabolism of Simvastatin can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Simvastatin can be increased when it is combined with Zofenopril.Experimental
ZucapsaicinThe serum concentration of Simvastatin can be increased when it is combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Avoid taking with grapefruit juice.

References

Synthesis Reference

Shieh-Shung J. Chen, Byron H. Arison, "Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs." U.S. Patent US4965200, issued April, 1981.

US4965200
General References
  1. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007 Jul 19;5:20. [PubMed:17640385]
External Links
Human Metabolome Database
HMDB05007
KEGG Drug
D00434
ChemSpider
49179
BindingDB
50139181
ChEBI
9150
ChEMBL
CHEMBL1064
Therapeutic Targets Database
DAP001519
PharmGKB
PA451363
HET
SIM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Simvastatin
ATC Codes
C10BX04 — Simvastatin, acetylsalicylic acid and ramiprilC10BA02 — Simvastatin and ezetimibeA10BH51 — Sitagliptin and simvastatinC10BA04 — Simvastatin and fenofibrateC10AA01 — SimvastatinC10BX01 — Simvastatin and acetylsalicylic acid
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
FDA label
Download (102 KB)
MSDS
Download (87.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHeart Failure, Unspecified1
0CompletedBasic SciencePeripheral Arterial Disease (PAD)1
0CompletedTreatmentCavernous Angioma, Familial / Cerebral Cavernous Hemangioma / Cerebral Cavernous Malformations1
0Enrolling by InvitationPreventionAtherosclerosis1
0RecruitingSupportive CareCancers / Tumors, Solid1
0RecruitingTreatmentProstate Cancer1
0Unknown StatusBasic ScienceHeart Failure, Unspecified / Hepatic Failure / Renal Failure / Respiratory Failure / Transplantations1
0WithdrawnTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1Active Not RecruitingTreatmentHealthy Volunteers1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailablePain, Chronic1
1CompletedNot AvailableType 2 Diabetes Mellitus2
1CompletedBasic ScienceDyslipidemias1
1CompletedBasic ScienceHealthy Participants1
1CompletedBasic ScienceHealthy Volunteers5
1CompletedBasic ScienceHuman Volunteers1
1CompletedBasic ScienceHypercholesterolaemia1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedHealth Services ResearchRheumatoid Arthritis1
1CompletedOtherType 2 Diabetes Mellitus2
1CompletedTreatmentAcute Kidney Injury (AKI)1
1CompletedTreatmentAlopecia Areata (AA)1
1CompletedTreatmentCholesterol, LDL / Hypercholesterolaemia1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentDrug Distribution1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers8
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHypercholesterolaemia / Hyperlipidemias1
1CompletedTreatmentHypercholesterolemia, Dyslipidemia1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentRheumatoid Arthritis1
1CompletedTreatmentSleep disorders and disturbances1
1CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1CompletedTreatmentType 2 Diabetes Mellitus2
1CompletedTreatmentViral Hepatitis B1
1Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach1
1RecruitingNot AvailableHealthy Volunteers1
1RecruitingTreatmentClear Cell Sarcoma of Soft Tissue / Ewing's Sarcoma (ES) / Germ Cell Tumors / Hepatoblastomas / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Renal Cell Adenocarcinoma / Retinoblastoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
1RecruitingTreatmentDyslipidemias / Peripheral Artery Disease (PAD)1
1RecruitingTreatmentType 2 Diabetes Mellitus1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedDiagnosticGluten Enteropathy1
1TerminatedPreventionAcute Coronary Syndromes (ACS) / Coronary Artery Disease / Depressive State1
1Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Inflammatory Reaction1
1Unknown StatusTreatmentPsychosis Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
1Unknown StatusTreatmentPulmonary Hypertension (PH)1
1, 2CompletedTreatmentDelayed Vasospasm / Subarachnoid Hemorrhage1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentPulmonary Hypertension (PH)1
1, 2CompletedTreatmentSickle Cell Disorders2
1, 2CompletedTreatmentSubarachnoid Hemorrhage1
1, 2RecruitingNot AvailableCoronary Microvascular Disease1
1, 2RecruitingTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis Complex (TSC)1
1, 2RecruitingTreatmentNon-segmental Vitiligo1
1, 2TerminatedSupportive CareChoroideremia1
1, 2WithdrawnTreatmentCystic Fibrosis (CF) / Systemic Inflammation1
2Active Not RecruitingPreventionAlzheimer's Disease (AD)1
2Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
2Active Not RecruitingTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage III Breast Cancer1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedBasic ScienceOxidative Stress1
2CompletedDiagnosticHealthy Volunteers1
2CompletedDiagnosticType 2 Diabetes Mellitus1
2CompletedPreventionAlzheimer's Disease (AD)1
2CompletedPreventionCancer, Breast2
2CompletedPreventionMigraines1
2CompletedPreventionNonvalvular Atrial Fibrillation1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCarotid Atherosclerosis1
2CompletedTreatmentColorectal Cancers / Metastasis1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Dyslipidemias1
2CompletedTreatmentDiabetic Polyneuropathy / Oxidative Stress1
2CompletedTreatmentDyslipidemias2
2CompletedTreatmentLiver Cirrhosis / Portal Hypertension1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMetastatic Brain Tumors1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentPsychosis Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
2CompletedTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2CompletedTreatmentThree Wall Intrabony Defects in Chronic Periodontitis1
2CompletedTreatmentVitiligo1
2RecruitingPreventionLiver Cirrhosis1
2RecruitingPreventionBone destruction / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentAcute Pancreatitis (AP) / Pancreatitis, Chronic / Recurrent Disease1
2RecruitingTreatmentAdenocarcinoma of Rectum1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentCessation, Smoking1
2RecruitingTreatmentCirrhoses, Liver1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentParkinson's Disease (PD)1
2TerminatedPreventionElevated LDL Cholesterol2
2TerminatedTreatmentAcute maxillary sinusitis caused by M. catarrhalis1
2TerminatedTreatmentBipolar Disorder (BD)1
2TerminatedTreatmentIntracerebral Hemorrhage1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)1
2Unknown StatusTreatmentAcute Myocardial Infarction (AMI)1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentColorectal Cancers2
2Unknown StatusTreatmentSepsis1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentProstate Cancer1
2WithdrawnTreatmentSevere Asthma1
2WithdrawnTreatmentSmoldering Multiple Myeloma (SMM)1
2, 3CompletedNot AvailablePre-Diabetic1
2, 3CompletedDiagnosticGluten Enteropathy1
2, 3CompletedPreventionStrokes / Transient Ischaemic Attack (TIA)1
2, 3CompletedPreventionSubarachnoid Hemorrhage1
2, 3CompletedTreatmentChronic Periodontitis2
2, 3CompletedTreatmentShock, Septic1
2, 3CompletedTreatmentTransplantation, Renal1
2, 3RecruitingTreatmentUveitis1
3CompletedDiagnosticCholesterol1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Heart Diseases / Hypertensive1
3CompletedPreventionAtherosclerosis / Hypercholesterolaemia / Hyperlipoproteinemia Type II1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Peripheral Arterial Disease (PAD)1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedPreventionRetinopathy, Diabetic1
3CompletedSupportive CarePolycystic Ovaries Syndrome1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAsthma Bronchial2
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentC Reactive Protein / Erectile Dysfunction (ED) / Vascular Disease Detected1
3CompletedTreatmentCardiovascular Disease (CVD)1
3CompletedTreatmentCardiovascular Disorder / Diabetes Mellitus (DM)1
3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Hypercholesterolaemia1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia2
3CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia / Type 2 Diabetes Mellitus1
3CompletedTreatmentCritical Illness1
3CompletedTreatmentDiabetic Dyslipidemia / Type 2 Diabetes Mellitus1
3CompletedTreatmentDyslipidemia, Hypercholesterolemia, Hypertriglyceridemia1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia3
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia / Hypertensive1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentFredrickson Type IIa & Type IIb Dyslipidaemia1
3CompletedTreatmentHeterozygous Familial Hypercholesterolemia1
3CompletedTreatmentHypercholesterolaemia16
3CompletedTreatmentHypercholesterolaemia / Hypertension,Essential1
3CompletedTreatmentHypercholesterolaemia / Hypertensive1
3CompletedTreatmentHypercholesterolaemia / Metabolic Syndromes1
3CompletedTreatmentHypercholesterolaemia / Myocardial Infarction (MI)1
3CompletedTreatmentHypercholesterolemia, Familial / Mixed hypercholesterolemia3
3CompletedTreatmentHyperlipidemias5
3CompletedTreatmentHyperlipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentHypertriglyceridemias2
3CompletedTreatmentIntestinal Neoplasms / Perioperative Care1
3CompletedTreatmentLiver Cirrhosis / Oesophageal varices haemorrhage / Portal Hypertension / Portal Vein Thrombosis1
3CompletedTreatmentLiver Cirrhosis / Portal Hypertension / Varices, Esophageal1
3CompletedTreatmentMalignant Neoplasm of Stomach1
3CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3CompletedTreatmentSubarachnoid Haemorrhage1
3CompletedTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentMixed hypercholesterolemia2
3Not Yet RecruitingTreatmentGraves Ophthalmopathy / Thyroid Associated Ophthalmopathy / Thyroid Associated Orbitopathy1
3RecruitingTreatmentEndothelial Dysfunction1
3RecruitingTreatmentHypercholesterolaemia1
3RecruitingTreatmentInfertilities1
3RecruitingTreatmentNoonan Syndrome1
3RecruitingTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
3TerminatedBasic ScienceAtherosclerosis / Hypercholesterolaemia1
3TerminatedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebrovascular Accidents / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction (MI)1
3TerminatedTreatmentDyslipidemias / Hypercholesterolaemia / Hyperlipidemias1
3TerminatedTreatmentDyslipidemias / Hypercholesterolemia, Familial1
3TerminatedTreatmentDyslipidemias / Hyperlipidemias1
3TerminatedTreatmentHypercholesterolaemia2
3TerminatedTreatmentHypercholesterolemia, Familial / Mixed hypercholesterolemia1
3TerminatedTreatmentHypertensive1
3TerminatedTreatmentPneumonia1
3TerminatedTreatmentPulmonary Disease, Chronic Obstructive1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusTreatmentCardiovascular Disease (CVD)1
3Unknown StatusTreatmentColorectal Cancers1
3Unknown StatusTreatmentCommunity Acquired Pneumonia (CAP)1
3Unknown StatusTreatmentDisseminated Sclerosis / Optic Neuritis1
3Unknown StatusTreatmentInflammatory Reaction1
3Unknown StatusTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3Unknown StatusTreatment[X]Statin Causing Adverse Effect in Therapeutic Use1
3WithdrawnTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypertriglyceridemias / Type 2 Diabetes Mellitus1
4CompletedNot AvailableCardiovascular Disease (CVD) / Cholesterol, LDL / Cognition / Type 2 Diabetes Mellitus1
4CompletedNot AvailableDyslipidemias1
4CompletedBasic ScienceAtherosclerosis1
4CompletedBasic ScienceCardiovascular Disease (CVD) / Diabetes Mellitus (DM)1
4CompletedDiagnosticHealthy Men1
4CompletedHealth Services ResearchDiabetes Mellitus (DM) / Dyslipidemias1
4CompletedHealth Services ResearchPeripheral Arterial Disease (PAD)1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Hypercholesterolaemia / Hyperlipidemias1
4CompletedPreventionEndothelial Dysfunction / Inflammatory Reaction / Myocardial Infarction (MI)1
4CompletedPreventionKidney Disease, Chronic1
4CompletedPreventionMyocardial Infarction (MI)1
4CompletedPreventionRenal Failure1
4CompletedTreatmentAtherosclerosis1
4CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Diabetes / Dyslipidemias / Strokes1
4CompletedTreatmentAtherosclerosis / Hypercholesterolaemia2
4CompletedTreatmentCardiovascular Disease (CVD)1
4CompletedTreatmentCardiovascular Disorder1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia1
4CompletedTreatmentDiabetes Mellitus (DM) / Impaired Renal Function1
4CompletedTreatmentDiastolic Dysfunction / Hypertensive1
4CompletedTreatmentDisseminated Sclerosis2
4CompletedTreatmentDyslipidemias1
4CompletedTreatmentFenofibrate/Simvastatin Comparison1
4CompletedTreatmentHypercholesterolaemia15
4CompletedTreatmentHypercholesterolaemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentHyperlipidemias1
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes3
4CompletedTreatmentMyocardial Infarction (MI)1
4CompletedTreatmentChronic, stable Angina pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentPostprandial Lipaemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentSchizophrenic Disorders1
4CompletedTreatmentStroke, Acute1
4CompletedTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingBasic ScienceHealthy Volunteers1
4RecruitingBasic ScienceCardiovascular Disease (CVD) / Diabetes Mellitus (DM)1
4RecruitingPreventionHypertensive / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingPreventionMild Cognitive Impairment (MCI)1
4RecruitingTreatmentBipolar Disorder (BD) / Cardiovascular Disease (CVD) / Major Depressive Disorder (MDD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Serious Mental Illness1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentMyocardial Fibrosis1
4RecruitingTreatmentPCOS, Insulin Resistance1
4RecruitingTreatmentPortal Hypertension1
4RecruitingTreatmentST Elevation Myocardial Infarction (STEMI)1
4SuspendedPreventionTraumatic Brain Injury (TBI)1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
4Unknown StatusPreventionCholesterol, HDL1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusPreventionHypertensive1
4Unknown StatusPreventionLiver Cirrhosis / Portal Hypertension2
4Unknown StatusTreatmentAtherosclerosis / Dyslipidemias1
4Unknown StatusTreatmentChronic Kidney Disease (CKD) / Hyperlipidemias1
4Unknown StatusTreatmentChronic Nephropathy / Hypercholesterolaemia1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Emphysema1
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertensive1
4Unknown StatusTreatmentHigh LDL Cholesterol Level / Systemic Lupus Erythematosus (SLE)1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentHypertensive2
4Unknown StatusTreatmentMetabolic Syndromes1
4Unknown StatusTreatmentPerioperative Inflammatory Response1
4Unknown StatusTreatmentPeritoneal dialysis therapy / Renal Failure, End Stage1
4Unknown StatusTreatmentShock, Septic1
4Unknown StatusTreatmentType 2 Diabetes Mellitus Without Insulin Treatment1
4Unknown StatusTreatmentMixed hypercholesterolemia1
4WithdrawnPreventionSchizoaffective Disorders / Schizophrenic Disorders1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Hyperlipidemias1
4WithdrawnTreatmentCardiovascular Risk Factors / Community Acquired Pneumonia (CAP)1
4WithdrawnTreatmentDyslipidemias1
4WithdrawnTreatmentGlucose Metabolism Disorders1
Not AvailableCompletedNot AvailableAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction (MI)1
Not AvailableCompletedNot AvailableAtherosclerosis / Carotid Artery Diseases / Coronary Artery Disease1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHypercholesterolaemia2
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD) / Diabetes / Hypercholesterolaemia1
Not AvailableCompletedBasic ScienceHeart Failure, Unspecified1
Not AvailableCompletedBasic ScienceHypercholesterolaemia1
Not AvailableCompletedBasic ScienceHyperglycemias1
Not AvailableCompletedOtherAnti Inflammatory Non-Steroidal / Cystic Fibrosis (CF) / Neutrophils1
Not AvailableCompletedPreventionAlzheimer's Disease (AD)1
Not AvailableCompletedPreventionAneurysms / Congenital Heart Disease (CHD) / Heart Valve Disease / Rheumatic Heart Disease1
Not AvailableCompletedPreventionCardiovascular Disease (CVD)1
Not AvailableCompletedPreventionDiabetic Nephropathies1
Not AvailableCompletedPreventionHeart Diseases1
Not AvailableCompletedPreventionHyperlipidemias1
Not AvailableCompletedTreatmentAtherosclerosis1
Not AvailableCompletedTreatmentBone Metastases of a Malignant Tumor1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Cerebrovascular Diseases / Peripheral Arterial Disease (PAD)1
Not AvailableCompletedTreatmentCardiovascular Risks / Hypercholesterolaemia / Inflammatory Reaction / Pre-Diabetic1
Not AvailableCompletedTreatmentCarotid Artery Diseases1
Not AvailableCompletedTreatmentCholesterol, LDL1
Not AvailableCompletedTreatmentChronic Renal Failure (CRF) / Hyperlipidemias / Hypertensive1
Not AvailableCompletedTreatmentDyslipidemias1
Not AvailableCompletedTreatmentHealthy Volunteers2
Not AvailableCompletedTreatmentInflammatory Reaction / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentMetabolic Syndromes / Obese / Sedentary1
Not AvailableCompletedTreatmentPeripheral Artery Disease (PAD)1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentStable Angina (SA)1
Not AvailableCompletedTreatmentMixed hypercholesterolemia / Type 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingTreatmentHyperlipidemias1
Not AvailableRecruitingDiagnosticGluten Enteropathy1
Not AvailableRecruitingPreventionCongenital Heart Disease (CHD) / Heart Valve Disease1
Not AvailableRecruitingTreatmentAtherosclerosis1
Not AvailableRecruitingTreatmentCirrhosis With Esophageal Varices / Cirrhosis With Large Esophageal Varices1
Not AvailableRecruitingTreatmentStatin Intolerance1
Not AvailableTerminatedNot AvailableCarotid Artery Diseases1
Not AvailableTerminatedPreventionAneurysmal Subarachnoid Hemorrhage / Cerebral Vasospasm1
Not AvailableTerminatedPreventionThoracic Pain1
Not AvailableTerminatedTreatmentCoronary Artery Disease1
Not AvailableTerminatedTreatmentMultiple Myeloma (MM)1
Not AvailableTerminatedTreatmentSchizophrenic Disorders1
Not AvailableUnknown StatusNot AvailableEndothelial Function1
Not AvailableUnknown StatusNot AvailableHypercholesterolaemia1
Not AvailableUnknown StatusBasic ScienceAcute Coronary Syndromes (ACS)1
Not AvailableUnknown StatusPreventionPre-Diabetic / Pre-Hypertension1
Not AvailableUnknown StatusScreeningCancers / Prostate1
Not AvailableUnknown StatusTreatmentPachyonychia Congenita1
Not AvailableUnknown StatusTreatmentPolycystic Ovaries Syndrome1
Not AvailableUnknown StatusTreatmentSmith-Lemli-Opitz Syndrome1
Not AvailableWithdrawnBasic ScienceHydroxymethylglutaryl-CoA Reductase Inhibitors / Myopathies1
Not AvailableWithdrawnPreventionAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)1
Not AvailableWithdrawnTreatmentAtherosclerosis1

Pharmacoeconomics

Manufacturers
  • Synthon pharmaceuticals ltd
  • Accord healthcare inc
  • Aurobindo pharma ltd
  • Dr reddys laboratories inc
  • Dr reddys laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lupin ltd
  • Matrix laboratories ltd
  • Perrigo r and d co
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Merck research laboratories div merck co inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
SuspensionOral20 mg/5mL
SuspensionOral40 mg/5mL
TabletOral5 mg
TabletOral80 mg
Tablet, film coated, extended releaseOral
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral80 mg/1
TabletOral
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral80 mg/1
Prices
Unit descriptionCostUnit
Zocor 90 40 mg tablet Bottle525.16USD bottle
Simvastatin 100% powder10.71USD g
Vytorin 10-20 mg tablet5.05USD tablet
Vytorin 10-40 mg tablet5.05USD tablet
Vytorin 10-10 mg tablet4.97USD tablet
Zocor 20 mg tablet4.69USD tablet
Zocor 80 mg tablet4.69USD tablet
Vytorin 10-80 mg tablet4.63USD tablet
Zocor 40 mg tablet4.11USD tablet
Simvastatin 20 mg tablet3.83USD tablet
Simvastatin 40 mg tablet3.83USD tablet
Simvastatin 80 mg tablet3.83USD tablet
Zocor 10 mg tablet2.89USD tablet
Simvastatin 10 mg tablet2.31USD tablet
Zocor 5 mg tablet1.99USD tablet
Simvastatin 5 mg tablet1.63USD tablet
Phl-Simvastatin 40 mg Tablet1.45USD tablet
Phl-Simvastatin 80 mg Tablet1.45USD tablet
Pms-Simvastatin 20 mg Tablet1.45USD tablet
Pms-Simvastatin 40 mg Tablet1.45USD tablet
Pms-Simvastatin 80 mg Tablet1.45USD tablet
Ran-Simvastatin 20 mg Tablet1.45USD tablet
Ran-Simvastatin 40 mg Tablet1.45USD tablet
Ran-Simvastatin 80 mg Tablet1.45USD tablet
Ratio-Simvastatin 20 mg Tablet1.45USD tablet
Ratio-Simvastatin 40 mg Tablet1.45USD tablet
Ratio-Simvastatin 80 mg Tablet1.45USD tablet
Sandoz Simvastatin 20 mg Tablet1.45USD tablet
Sandoz Simvastatin 40 mg Tablet1.45USD tablet
Sandoz Simvastatin 80 mg Tablet1.45USD tablet
Apo-Simvastatin 20 mg Tablet1.45USD tablet
Apo-Simvastatin 40 mg Tablet1.45USD tablet
Apo-Simvastatin 80 mg Tablet1.45USD tablet
Co Simvastatin 20 mg Tablet1.45USD tablet
Co Simvastatin 40 mg Tablet1.45USD tablet
Co Simvastatin 80 mg Tablet1.45USD tablet
Jamp-Simvastatin 20 mg Tablet1.45USD tablet
Jamp-Simvastatin 40 mg Tablet1.45USD tablet
Jamp-Simvastatin 80 mg Tablet1.45USD tablet
Mylan-Simvastatin 20 mg Tablet1.45USD tablet
Mylan-Simvastatin 40 mg Tablet1.45USD tablet
Mylan-Simvastatin 80 mg Tablet1.45USD tablet
Novo-Simvastatin 20 mg Tablet1.45USD tablet
Novo-Simvastatin 40 mg Tablet1.45USD tablet
Novo-Simvastatin 80 mg Tablet1.45USD tablet
Phl-Simvastatin 20 mg Tablet1.45USD tablet
Apo-Simvastatin 10 mg Tablet1.17USD tablet
Co Simvastatin 10 mg Tablet1.17USD tablet
Jamp-Simvastatin 10 mg Tablet1.17USD tablet
Mylan-Simvastatin 10 mg Tablet1.17USD tablet
Novo-Simvastatin 10 mg Tablet1.17USD tablet
Phl-Simvastatin 10 mg Tablet1.17USD tablet
Pms-Simvastatin 10 mg Tablet1.17USD tablet
Ran-Simvastatin 10 mg Tablet1.17USD tablet
Ratio-Simvastatin 10 mg Tablet1.17USD tablet
Sandoz Simvastatin 10 mg Tablet1.17USD tablet
Apo-Simvastatin 5 mg Tablet0.59USD tablet
Co Simvastatin 5 mg Tablet0.59USD tablet
Jamp-Simvastatin 5 mg Tablet0.59USD tablet
Mylan-Simvastatin 5 mg Tablet0.59USD tablet
Novo-Simvastatin 5 mg Tablet0.59USD tablet
Phl-Simvastatin 5 mg Tablet0.59USD tablet
Pms-Simvastatin 5 mg Tablet0.59USD tablet
Ran-Simvastatin 5 mg Tablet0.59USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5846966No1993-09-212013-09-21Us
US7326708No2006-04-112026-04-11Us
US6080428No1997-05-272017-05-27Us
US6469035No1998-03-152018-03-15Us
US6699871No2002-07-262022-07-26Us
US7125873No2002-07-262022-07-26Us
USRE37721Yes1997-04-252017-04-25Us
USRE42461Yes1997-04-252017-04-25Us
US6303661No1997-04-242017-04-24Us
US6890898No1999-02-022019-02-02Us
US7078381No1999-02-022019-02-02Us
US7459428No1999-02-022019-02-02Us
US8168637No2002-06-262022-06-26Us
US9597289No2010-02-232030-02-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)135-138 °CPhysProp
water solubilityInsoluble FDA label
logP4.68HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.51ALOGPS
logP4.46ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)14.91ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.68 m3·mol-1ChemAxon
Polarizability47.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9475
Blood Brain Barrier+0.9422
Caco-2 permeable-0.5951
P-glycoprotein substrateSubstrate0.8508
P-glycoprotein inhibitor IInhibitor0.7335
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.8435
CYP450 2C9 substrateNon-substrate0.835
CYP450 2D6 substrateNon-substrate0.9254
CYP450 3A4 substrateSubstrate0.7513
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9307
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.792
CarcinogenicityNon-carcinogens0.9408
BiodegradationNot ready biodegradable0.9657
Rat acute toxicity2.0061 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8921
hERG inhibition (predictor II)Non-inhibitor0.8573
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-3900000000-d04758924bf88a90c017
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fya-0988400000-d9778b2f11696b81fb07
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006w-0790000000-4f23e0376d85845e0964
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05i1-0940000000-058f6298af54c05532ed
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0092-0910000000-6ecd838b2f6fddf67dad
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0597-0900000000-012d0d6fcabbd21d696d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000e-0590000000-7f99e0b9531d4f42831a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0092-1960000000-e8429bbec985c5ecdd2d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0592-1910000000-dc09a51ca37fe4d24a5a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abd-1900000000-9b55821f49270e5dd598
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0536-1900000000-d8a41a97ccbdb30e5a5e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002f-2900000000-abe04d7f99c3eb0f2fcb

Taxonomy

Description
This compound belongs to the class of organic compounds known as delta valerolactones. These are cyclic organic compounds containing an oxan-2- one moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactones
Sub Class
Delta valerolactones
Direct Parent
Delta valerolactones
Alternative Parents
Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Delta valerolactone / Fatty acid ester / Delta_valerolactone / Dicarboxylic acid or derivatives / Oxane / Fatty acyl / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative / Oxacycle
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
statin (semi-synthetic), fatty acid ester, delta-lactone, carbobicyclic compound (CHEBI:9150)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Cenedella RJ, Kuszak JR, Al-Ghoul KJ, Qin S, Sexton PS: Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats. J Lipid Res. 2003 Jan;44(1):198-211. [PubMed:12518039]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA: Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002 Dec;30(12):1400-5. [PubMed:12433810]
  4. Liu L, Zhang R, Zhao JJ, Rogers JD, Hsieh JY, Fang W, Matuszewski BK, Dobrinska MR: Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. J Pharm Biomed Anal. 2003 Apr 24;32(1):107-23. [PubMed:12852453]
  5. Pappu AS, Bacon SP, Illingworth DR: Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. J Lab Clin Med. 2003 Apr;141(4):250-6. [PubMed:12677170]
  6. Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L: [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol. 2003 Feb;130(2 Pt 1):187-90. [PubMed:12671581]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other
General Function
Protein kinase binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fi...
Gene Name
ITGB2
Uniprot ID
P05107
Uniprot Name
Integrin beta-2
Molecular Weight
84781.08 Da
References
  1. Fujii T, Masuyama K, Kawashima K: Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways. J Neuroimmunol. 2006 Oct;179(1-2):101-7. Epub 2006 Jul 10. [PubMed:16828882]
  2. Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function-associated antigen-1 in the regulation of lymphocytic cholinergic activity. Life Sci. 2007 May 30;80(24-25):2320-4. Epub 2007 Jan 17. [PubMed:17289088]
  3. Katano H, Pesnicak L, Cohen JI: Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4960-5. Epub 2004 Mar 23. [PubMed:15041742]
  4. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. Clin Immunol. 2005 Sep;116(3):211-6. [PubMed:15936988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated ...
Gene Name
ITGAL
Uniprot ID
P20701
Uniprot Name
Integrin alpha-L
Molecular Weight
128768.495 Da
References
  1. Katano H, Pesnicak L, Cohen JI: Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4960-5. Epub 2004 Mar 23. [PubMed:15041742]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  7. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259]
  2. Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT: Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8. [PubMed:15998357]
  3. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6. [PubMed:11474784]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  3. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T: Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 Sep;21(9):1686-91. [PubMed:15497697]
  4. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  2. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH: Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20. [PubMed:22186618]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13